Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gushengtang HoldingsHKSE:02273 +2.29%88 EBITDA Margin % is 20.56% as of Dec. 2025, which is 441% above its 10-year median of 3.80. GuruFocus rates HKSE:02273 with a GF Score™ of 88/100 and a GF Value™ of HK$59.17 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Gushengtang Holdings ranks better than 72.89% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Gushengtang Holdings EBITDA Margin % Related Terms
Gushengtang Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Gushengtang Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02273 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Gushengtang Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gushengtang Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Gushengtang Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Gushengtang Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gushengtang Holdings (HKSE:02273) has a EBITDA Margin % of 20.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gushengtang Holdings and its competitors. This is 441% above median its historical median of 3.80. According to the industry distribution chart, Gushengtang Holdings ranks #180 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 27.1%.
Is Gushengtang Holdings' EBITDA Margin % too high?
Gushengtang Holdings' current EBITDA Margin % of 20.56% is 441% above median its 10-year median of 3.80. The Healthcare Providers & Services industry median EBITDA Margin % is 10.16. Gushengtang Holdings' value of 20.56% is 102.4% above this industry median. Based on the distribution chart, Gushengtang Holdings ranks #180 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Gushengtang Holdings has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gushengtang Holdings' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Gushengtang Holdings ranks #180 out of 664 companies for EBITDA Margin %. This puts Gushengtang Holdings in the upper half of its industry. The industry median EBITDA Margin % is 10.16. Gushengtang Holdings' value of 20.56% is 102.4% above this benchmark. While the company's 10-year median is 3.80 vs. the industry median of 10.16, Gushengtang Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.16, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gushengtang Holdings's current EBITDA Margin % of 20.56% is 102.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Gushengtang Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gushengtang Holdings's current EBITDA Margin % is 20.56%, which is 441% above median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gushengtang Holdings stock overvalued right now?
Based on GuruFocus' analysis, Gushengtang Holdings (HKSE:02273) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$59.17, compared to a current price of HK$27.70 — trading 53.2% below its estimated fair value. The current EBITDA Margin % is 20.56%, which is 441% above median its 10-year median of 3.80 and 102.4% above the Healthcare Providers & Services industry median of 10.16. Gushengtang Holdings' overall GF Score™ is 88/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Gushengtang Holdings (HKSE:02273), the current EBITDA Margin % is 20.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gushengtang Holdings (HKSE:02273) Overvalued in 2026?
Based on GuruFocus' analysis, Gushengtang Holdings stock appears to be undervalued.
The current stock price of HK$27.70 is trading 53.2% below its estimated GF Value™ of HK$59.17.
GuruFocus considers Gushengtang Holdings to be Significantly Undervalued.
Key valuation signals for HKSE:02273:
EBITDA Margin %: 20.56% (441% above median its 10-year median of 3.80)
GF Value™: HK$59.17 vs. price of HK$27.70 (53.2% below fair value)
Industry Position: 102.4% above the Healthcare Providers & Services median (#180 of 664)
No single metric tells the full story. See the HKSE:02273 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gushengtang Holdings Ltd is a traditional chinese medicine (TCM) company. Through offline medical institutions and online healthcare platforms, it provides customers with a comprehensive range of TCM healthcare services and products to address diverse medical and healthcare management needs. All of the group's revenue is derived from the PRC.
88GF Score
Get the complete analysis for HKSE:02273
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02273 has been successfully added to your 
